CoronaryAtlas logo
CoronaryAtlas
Transthyretin
Pathway / Off-pathway / systemic markers

Transthyretin

TTRprotein

Transthyretin amyloidosis and aggregation associates with cardiovascular risk independent of atherothrombotic plaque pathology.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleSystemic risk marker; associates with cardiovascular disease but acts via amyloid burden, not atherothrombotic cascade.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
50
A — assay feasibility
68
E — evidence strength
40
T1DI (composite)
9
Specificity differential (R−C)-35
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 1
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 1
Coverage: 4/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 9 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(1)